Global DIA’s Sorcha McCrohan, contributing to the the August 2024 edition of DIA’s Global Forum magazine, reviews insights from the town hall meetings that brought together regulators from around the world at the organization’s Global Annual Meeting 2024. Regulators worldwide recently convened in San Diego for DIA’s Global Annual Meeting 2024 to…
Switzerland Switzerland, home to industry giants like Novartis and Roche, boasts a thriving pharma industry that generates some seven percent of the country’s GDP, as well as a flourishing biotech scene. However, all is not so well in Switzerland’s domestic healthcare landscape, where surging insurance premiums and drug costs mean that…
Global Recently appointed ISPOR President Eberechukwu Onukwugha, PhD, lays out her inclusive vision for the organisation’s future, championing health economic and outcomes research excellence and innovation that works for all. The original version of this article featured in the July/August edition of ISPOR’s Value & Outcomes Spotlight magazine. As I…
China Writing in the July 2024 edition of DIA’s Global Forum magazine Mingcan DU and Fengyun (Vicky) HAN of Johnson & Johnson Global Regulatory Policy and Intelligence look back at the evolution of the use of real-world evidence (RWE) in regulatory decision-making in China, including key use cases and future prospects.…
Africa The IFPMA’s Sarah Adam, writing in the July 2024 edition of DIA’s Global Forum magazine, looks back on an insightful discussion on the progress towards an African Medicines Agency at the DIA Europe conference earlier this year. The African Medicines Agency (AMA) is paving the way for Africa to achieve…
United Kingdom The newly elected UK government’s Secretary of State for Health and Social Care Wes Streeting has a full plate of challenges ahead. Britain’s National Health Service (NHS) is plagued with a chronic lack of funding, staffing crunches and backlogs, while the country’s life sciences sector is seemingly in decline. Streeting…
Spain Some of the biggest stories coming out of Spain’s pharma industry, including Brookfield’s bid for a troubled Grifols; Esteve’s Spanish plant expansion; Rovi’s offers for a potential buyout of its CDMO business, and the EUR 90 million earmarked by Spain’s Ministry of Science, Innovation and Universities (MICIU) to promote biomedical…
USA AbbVie, for only the second time in its history, has a new CEO. Having been led by Richard A. Gonzalez since its inception in 2013, the organization has named former president and chief operating officer Robert A. Michael as its new leader. As he takes on the role this month,…
USA The Promising Pathways Act 2.0 is a newly proposed bill that aims to expedite and streamline approval pathways for rare disease therapies in the US. The Act is, however, facing a number of challenges in terms of implementation. The sponsors of these niche therapies tend to be small and medium-sized…
Global Brendan Shaw paints a concerning picture of global health priorities post-pandemic, highlighting the need for renewed focus and investment in healthcare systems to prevent further backsliding. “There isn’t a financing gap. There is just money that is not moving towards the right things. There’s plenty of money out there”…
China Writing exclusively for PharmaBoardroom, Song Ruilin of the China Pharmaceutical Innovation and Research Development Association (PhIRDA) outlines some of the key improvements and optimisations in the regulatory landscape for pharmaceutical innovation in China. Professor Song also notes the major impact that Chinese innovation is having on global R&D pipelines and…
Europe As the EU’s push to harmonise clinical assessments across its 27 member states moves from the initial Health Technology Assessment (HTA) regulation in 2022 to the European Joint Clinical Assessment (JCA) process that will come into effect in January, European HTA authorities and industry leaders weigh in on the implications.…
See our Cookie Privacy Policy Here
